Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs, with growth profiles that stack up favorably against many AI darlings on a fundamentals basis. The three names below all reported Q4 2025 results in February, all have approved products generating meaningful revenue, and all carry catalysts that should drive the story through 2026 and beyond.
The screen is straightforward: an approved, commercially active drug; durable revenue growth in the most recent quarter; visible 2026 catalysts; and a multi-year runway that does not depend on a hyperscaler capex cycle.
1. Cytokinetics (CYTK)
Cytokinetics (NASDAQ:CYTK | CYTK Price Prediction) is the most speculative of the three, but it just crossed the most important line in biotech. MYQORZO (aficamten) received FDA approval in December 2025, and the U.S. launch is underway. Q4 2025 revenue came in at $17.75 million, beating the $8.02 million consensus by 121%, driven by milestone payments under the Sanofi license agreement. EPS of -$1.50 missed the -$1.37 estimate as the company built out its commercial infrastructure.
The financial profile carries real risk. Shareholders’ equity sits at -$659.63 million, and 2026 guidance calls for combined GAAP R&D and SG&A of $830 million to $870 million. The offset is a calendar of catalysts: ACACIA-HCM topline results in Q2 2026, a German MYQORZO launch in Q2, and a potential MAPLE-HCM sNDA approval in Q4 2026. CEO Robert Blum called the quarter “a defining moment” for the company’s transition to commercial stage. Wall Street agrees, with an analyst target of $92.94 against a recent price near $62.29. Shares are up 44% over the past year.
2. Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals (NASDAQ:MDGL) is running one of the most successful specialty launches in recent memory. Rezdiffra, the first approved MASH therapy, posted Q4 2025 net sales of $321.10 million, up 211% year over year, and full-year 2025 revenue of $958.40 million versus $180.10 million in 2024, growth of 432%. The patient base climbed from 17,000 in Q1 to more than 36,250 by year-end, with over 10,000 prescribing healthcare providers.
CEO Bill Sibold framed the opportunity bluntly: “We solidified our position as the undisputed leader in MASH highlighted by nearly $1 billion in Rezdiffra sales in its first full year of launch. And we’re just getting started.” Roughly 90% of the target MASH population remains untreated, and the company has extended U.S. patent protection to 2045. The pipeline spans more than 10 programs, with MGL-2086 entering the clinic in Q2 2026 and MAESTRO-NASH OUTCOMES topline data due in 2027.
The catch: Madrigal remains unprofitable, with full-year operating income of -$300.10 million and a forward P/E of 667x. Analysts see upside anyway, with a target of $672.79 against a recent $514.41.
3. ADMA Biologics (ADMA)
ADMA Biologics (NASDAQ:ADMA) takes the top slot because it is the only profitable name on the list, backed by multi-year guidance. Q4 2025 revenue came in at $139.16 million, up 18% year over year, EPS of $0.20 met expectations, and adjusted EBITDA jumped 52% to $73.59 million. Gross margin expanded to 64% from 54% as yield-enhanced production fully integrated into commercial operations. Full-year 2025 revenue was $510.17 million, up 20%, with net income of $146.93 million.
ASCENIV is the engine, generating $362.53 million in 2025, up 51%, with management noting it remains early in its penetration curve. Guidance calls for 2026 revenue above $635 million, 2027 above $775 million, and 2029 above $1.1 billion with adjusted EBITDA of at least $700 million, implying roughly 20% revenue and 30% EBITDA CAGRs. Capital returns are real: a $200 million repurchase program including a $125 million accelerated agreement with JPMorgan. CEO Adam Grossman said ADMA is “entering 2026 with significant momentum”.
Valuation is the most reasonable in the group: a trailing P/E of 18x and a forward P/E of 11x. Shares have been down 41.16% year to date, but rallied 14.47% over the past month since the Q4 print. Analysts carry a target of $20.67.
The Bottom Line
Cytokinetics offers the most catalyst-rich 2026 calendar but the weakest balance sheet. Madrigal owns the MASH category outright with a launch that annualized above $1 billion within six quarters. ADMA earns the top spot by combining growth with actual earnings, margin expansion, capital returns, and the only multi-year revenue and EBITDA targets in the group. For investors looking past the AI trade, that combination is what respectable growth actually looks like.
Top Gaining Stocks
Top Losing Stocks